Dr. John Olson, Md

Member of

Search for Dr. John Olson, Md, Neurosurgery, Saint Joseph, MO.

Member of

The search results for your inquiry are provided below, along with Sources for further clarification.

Overview

Practice

About

FAQ

Accepts new patients

Is this you? Manage your online reputation

Please wait while we find reviews for your provider...

Specialties

Neurosurgery

LocationSaint Joseph, MO

Bio:

With over 33 years of unparalleled expertise in neurosurgery, this com...

Experience:

30+ years

Languages Spoken:

English,

Spanish

[16]

Common Treatments:

Back Pain

Brain Tumor

Cerebrovascular Disease

See More

Institutes Attended:

UK,

ABOS,

IDFPR-MB

Certificates:

MD,

Intern,

Res

[16]

See More

NPI/License number:

1568494771

Hospital Affiliations:

Blessing Hospital

See More

AZ Awards:

Sex:

male

This is an AZ search result. This provider is not affiliated, endorsing or endorsed by AZcare, Please verify key information.

Common Treatments:

Back Pain

Brain Tumor

Cerebrovascular Disease

Cervical Spinal Stenosis

Cranial Trauma

Degenerative Disc Disease

Epilepsy

Herniated Disc

See More

Institutes Attended:

UK,

ABOS,

IDFPR-MB

Certificates:

MD,

Intern,

Res

[16]

See More

NPI/License number:

1568494771

Hospital Affiliations:

Blessing Hospital

See More

AZ Awards:

Sex:

male

Overview

Dr. John Olson is a highly experienced and compassionate neurosurgeon dedicated to providing exceptional care. With over 33 years of experience, Dr. Olson brings a wealth of knowledge and expertise to his practice. He is affiliated with Blessing Hospital and Mosaic Medical Center In Saint Joseph, ensuring patients have access to state-of-the-art facilities. Dr....

Practice

In-network insurance

[3][2]

Aetna

Alliant Health Plans

Ambetter

Anthem

Aspire Health Plan

Blue Cross Blue Shield

Insurance info is for reference only. Contact the provider to confirm they accept your plan, as some may decline certain insurances even if technically in-network.

Appointments Scheduling

[16]

Blessing Hospital

In-Person Visit

Address:

1005 Broadway St, Quincy, IL 62301

Phone:

(217) 223-8400

Fax:

(217) 223-3041

[16]

Practice At 802 N Riverside Rd Suite 150

In-Person Visit

Address:

802 N Riverside Rd Ste 150, Saint Joseph, MO 64507

Phone:

(816) 271-4025

Fax:

(816) 271-4026

[16]

Blessing Health-48th

In-Person Visit

Address:

4800 Maine St, Quincy, IL 62305

Phone:

(217) 224-6423

Fax:

(217) 214-5881

About

NPI/License number:

1568494771

[15]

Experience:

30+ years

Languages Spoken:

English,

Spanish

[16]

Hospital Affiliations:

[16]

Blessing Hospital

Mosaic Medical Center In Saint Joseph

Specialties:

Neurosurgery

General Neurosurgery

Neurological Surgery

Common Treatments:

Back Pain

See More

Education & Certifications:

Residency in Neurological Surgery

University of Kansas School of Medicine1995

Internship in Neurological Surgery

University of Kansas School of Medicine1991

Medical Degree

University of Kansas School of Medicine1990

Certified in Neurological Surgery

American Board of Neurological Surgery

See More

Publications:

Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor.

This article reports a case of a 15-year-old boy with severe Factor VIII deficiency and an inhibitor who developed acute myocardial infarction (AMI) after five days of treatment with activated prothrombin complex concentrate (FEIBA). Initially hospitalized for a suspected retroperitoneal hemorrhage, he received high doses of FEIBA, improving bleeding symptoms. However, on day five, he developed clinical signs of AMI, confirmed by ECG changes (widespread ST elevation) and elevated cardiac enzymes. Despite intensive care and initial recovery, he progressed to severe congestive heart failure with dilated cardiomyopathy and underwent successful cardiac transplantation five months later. Histopathology showed fibrosis and wavy fibers but no hemorrhage, thrombosis, or coronary artery disease. The authors review nine similar reported cases of AMI after PCC treatment, often in young patients without typical coronary risk factors. Unlike classic atherosclerotic AMI, these cases lacked evidence of coronary artery disease or thrombosis. Clotting studies revealed no significant hypercoagulability or disseminated intravascular coagulation. The myocardial injury’s pathogenesis remains unclear but may involve mechanisms other than thrombosis, such as coronary vasospasm or inflammation. The authors stress caution with activated PCCs, especially regarding dosage and duration, given the risk of potentially fatal myocardial complications despite the absence of conventional coronary artery disease.

By Stephen I. Chavin + 3 more

01-08-1988

Pharmacokinetics of orally administered zidovudine among patients with hemophilia and a symptomatic human immunodeficiency virus (HIV) infection

This 1989 study investigates the pharmacokinetics of orally administered zidovudine (ZDV), an antiretroviral drug, in eight asymptomatic HIV-infected hemophilia patients. Given that many hemophilia patients had HIV infections from contaminated factor VIII treatments and also suffer from chronic hepatitis, the researchers aimed to understand ZDV metabolism in this specific group due to concerns about altered hepatic drug processing and toxicity. Each patient received a single 300 mg oral dose of ZDV, and serum levels of ZDV and its glucuronide metabolite (GZDV) were measured over 24 hours using HPLC. Results showed rapid absorption of ZDV with peak serum levels around 0.5 hours (mean ~2052 ng/ml), while GZDV peaked at 1 hour (mean ~4751 ng/ml). The drug and metabolite exhibited biexponential decline within 4 hours; thereafter, three patients showed a simple log-linear decay, but five showed a more complex tri-exponential elimination with a mean terminal half-life of 4.8 hours. No correlation was found between liver enzyme elevations and drug kinetics. The wide interpatient variability in serum ZDV concentrations suggests that therapeutic drug monitoring could be useful. Furthermore, the extended elimination half-life may justify less frequent dosing in some hemophilia patients. This study informs tailored ZDV therapy in this vulnerable population.

By Gene D. Morse + 5 more

01-03-1989

Role of early edema in the development of regional seizure-related brain damage.

This 1987 study by Nelson and Olson explores the role of early brain edema in seizure-related brain damage using a kainic acid-induced seizure model in rats. They measured brain edema in temporal cortex, hippocampus, parietal cortex, and dorsal thalamus by assessing tissue specific gravity, which reflects water content. Following a 1-hour seizure, early generalized edema appeared 2 hours post-seizure, with the largest volume increase (~4%) in hippocampus. Over 24 to 48 hours, progressive necrotic (vasogenic) edema developed predominantly in temporal cortex (31-42% volume increase) and to a lesser extent in hippocampus, corresponding with histological evidence of cell damage. Mannitol administration during seizures showed protective effects: hypertonic mannitol prevented early edema in temporal and parietal cortex and completely blocked necrotic edema in temporal cortex and hippocampus, suggesting early edema contributes to later tissue damage. However, water intoxication induced severe generalized edema without subsequent necrosis, indicating that edema alone is insufficient to cause damage. The findings imply that mannitol’s neuroprotection may involve mechanisms beyond simple dehydration, potentially by preventing vascular and microcirculatory disturbances linked to early cytotoxic edema. This study provides quantitative evidence that early edema plays a critical role in seizure-induced brain injury, highlighting mannitol’s therapeutic potential.

By Stanley R. Nelson + 1 more

01-06-1987

Reviews

Aggregated Ratings: 4.8

Positive feedback

Neutral feedback

Negative feedback

FAQ

Dr. Olson specializes in Neurological Surgery, General Neurosurgery, and Surgery. He is board certified by the American Board of Neurological Surgery.

He treats brain cancer, spinal stenosis, herniated discs, brain abscess, cerebral edema, hydrocephalus, cervical spine myelopathy, degenerative disc disease, low back pain, meningiomas, and various other neurological conditions.

He performs brain surgery, brain tumor biopsy, spinal fusion, craniotomy, spinal cord stimulation, lamina procedures, neuroplasty, neurostimulation, spinal nerve blocks, carpal tunnel decompression, and various other neurosurgical procedures.

Yes, he has particular expertise in brain and spine surgery, including treatment of brain tumors, spinal disorders, back and neck pain, and complex neurological conditions.

Patients praise his compassionate approach, thorough explanations, and ability to put patients at ease. He takes time to explain procedures clearly and provides comprehensive post-surgical care.

He practices at multiple locations: 802 N Riverside Rd Suite 150, Saint Joseph, MO 64507; Blessing Hospital in Quincy, IL; and Blessing Health-48th in Quincy, IL.

He earned his MD from University of Kansas School of Medicine (1990), completed his internship in Neurological Surgery (1990-1991) and residency (1991-1995) at the University of Kansas School of Medicine.

Dr. Olson speaks English and Spanish.

He accepts many major insurance plans including Aetna, Anthem, Blue Cross Blue Shield, Cigna, Curative, Delta Dental, First Health, HAP Insurance, Humana, and UnitedHealthcare.

He has an exceptional rating of 4.81 out of 5 from 37 reviews. Patients particularly praise his compassionate care, surgical expertise, and ability to explain procedures clearly. One patient noted being completely pain-free after surgery.